PLIANT THERAPEUTICS, INC. Cash Flow Statement
PLRX|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
PLIANT THERAPEUTICS, INC. used $156M in operating cash flow and negative free cash flow of $159M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -4.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$210.3M | -$123.3M | -$97.3M | -$97.3M | -$631.0K | -$631.0K |
| Depreciation & Amortization | $2.1M | $1.8M | $1.5M | $1.5M | $1.1M | $1.1M |
| Operating Cash Flow | -$155.5M | -$94.6M | -$75.4M | -$75.4M | -$2.8M | -$2.8M |
| Capital Expenditures | $3.8M | $1.8M | $2.0M | $2.0M | $964.0K | $964.0K |
| Free Cash Flow | -$159.4M | -$96.4M | -$77.4M | -$77.4M | -$3.7M | -$3.7M |
| FCF Margin | - | -995.3% | -1022.1% | -1022.1% | -6.5% | -6.5% |